Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMZPEHY)

Drug Name
Multi-epitope peptide melanoma vaccine Drug Info
Synonyms
Multi-epitope peptide melanoma vaccine (MART-1, gp100, tyrosinase); Multi-epitope peptide melanoma vaccine (MART-1, gp100, tyrosinase), University of Pittsburgh; MART-1 (51-73) + MART-1(27-35); MART-1(NSC-672643), gp100(NSC-683472), tyrosinase (NSC-699048); MGT (MART-1 (27-35), gp100(209-217, 210M), tyrosinase (368-376, 370D)); (MART-1, gp100, tyrosinase) + (IFNalfa2b + GM-CSF); (MART-1, gp100, tyrosinase) + GM-CSF; (MART-1, gp100, tyrosinase) + IFNalfa2b
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DMZPEHY

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
MART-1 melanoma antigen (MLANA) TT362RB MAR1_HUMAN Not Available [2]
Melanocytes lineage-specific antigen GP100 (PMEL) TT8MK59 PMEL_HUMAN Not Available [2]
Tyrosinase (TYR) TTULVH8 TYRO_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Tyrosinase (TYR) DTT TYR 5.959 5.711 5.973 4.912
Melanocytes lineage-specific antigen GP100 (PMEL) DTT PMEL 5.885 5.225 6.079 5.959
MART-1 melanoma antigen (MLANA) DTT MLANA 5.361 5.115 4.926 4.954
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification 02 Neoplasm
Disease Class ICD-11: 2C82 Prostate cancer
The Studied Tissue Skin
The Studied Disease Melanoma [ICD-11:2C82]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Tyrosinase (TYR) DTT TYR 6.68E-04 2.54 1.15
Melanocytes lineage-specific antigen GP100 (PMEL) DTT PMEL 1.08E-03 1.89 1.06
MART-1 melanoma antigen (MLANA) DTT MLANA 3.29E-02 1.64 0.76
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT00036816) Vaccine Therapy in Treating Patients With Melanoma of the Eye. U.S. National Institutes of Health.
2 Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in-adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. Correction in: volume 35 on page 650.